Chemotherapy-Free Options Remain Unmet Need in Colorectal Cancer
Zev A. Wainberg, MD, explains the importance of having a chemotherapy-free option available for patients with colorectal cancer.
Zev A. Wainberg, MD, assistant professor of Medicine at the University of California Los Angeles, explained the importance of having a chemotherapy-free option available for patients with colorectal cancer.
Currently, 2 chemotherapy regimens are widely used as treatment of patients with colorectal cancer, including the FOLFIR regimen (irinotecan, fluorouracil (5-FU), and folinic acid [leucovorin]) and the FOLFIRNOX regimen (Folinic acid, fluorouracil, irinotecan, and oxaliplatin). Wainberg says that many oncologists are now hoping for individualized options.
One agent, regorafenib (Stivarga) is FDA approved for the treatment of colorectal cancer, but beyond regorafenib, there are no FDA approved options. There is also limited clinical trial data regarding the efficacy and safety of investigational targeted therapies for the treatment of this population.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Tumor Treating Fields Show Significant Survival Benefit in Pancreatic Cancer
December 2nd 2024The PANOVA-3 trial demonstrated a significant 2-month overall survival improvement when adding tumor treating fields to gemcitabine and nab-paclitaxel for patients with locally advanced pancreatic adenocarcinoma.
Read More
